Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2018
The 8th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2018 in Geneva, Switzerland
Presentation Date(s):- Apr 11 - 14, 2018
- Total Presentations: 407
-
+
Resistance to TKIs
- Type: Educational session
- Presentations: 5
- Moderators:T.S.K. Mok
- Coordinates: 4/13/2018, 11:00 - 12:30, Room B
-
+
General mechanisms of resistance
11:00 - 11:20 | Presenter: T. Mitsudomi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Therapeutic strategies to overcome EGFR
11:20 - 11:40 | Presenter: T.S.K. Mok
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Therapeutic strategies to overcome ALK and ROS1
11:40 - 12:00 | Presenter: S. Ortiz-Cuaran
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Focus on local treatment options
12:00 - 12:20 | Presenter: F. McDonald
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
Poster Display session (Friday)
- Type: Poster Display session
- Presentations: 197
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
-
+
Tumour biology and pathology
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
4P - Assessment of PD-L1 expression by immunohistochemistry in histological and cytological non-small cell lung carcinoma (NSCLC) in the era of immunotherapy: A national Irish study
12:30 - 12:30 | Presenter: A. Fabre
- Abstract
Loading... -
+
5P - Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of non-small cell lung cancer
12:30 - 12:30 | Presenter: Y. Saito
- Abstract
Loading... -
+
6P - Mechanisms of regulating PD-L1 expression in non-small cell lung cancer during EMT process
12:30 - 12:30 | Presenter: F. Li
- Abstract
Loading... -
+
7P - The regulation of FOXP3 expression by GLI-1 in non-small cell lung cancer cells and its influence on lung cancer cell stemness
12:30 - 12:30 | Presenter: H. Qi
- Abstract
Loading... -
+
8P - Noncanonical Wnt11, a tumor suppressive gene by antagonizing canonical Wnt signaling, represents a putative molecularly therapeutic target in lung cancer
12:30 - 12:30 | Presenter: X. Wang
- Abstract
Loading... -
+
9P - Mesenchymal stem cells’ microvesicles from primary and metastatic NSCLC niches differentially modulate lung cancer cells
12:30 - 12:30 | Presenter: O. Attar-Schneider
- Abstract
Loading... -
+
10P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact
12:30 - 12:30 | Presenter: R. Shemesh
- Abstract
Loading... -
+
11P - Glycolysis enzyme screenings identify non-glycolytic function of aldolase A that interacts and alters F-actin dynamics to promote lung cancer metastasis
12:30 - 12:30 | Presenter: Y. Chang
- Abstract
Loading... -
+
12P - Cigarette smoke promotes proliferation of non-small cell lung cancer (NSCLC) via enhancing glucose uptake and glycolysis
12:30 - 12:30 | Presenter: I. Hsieh
- Abstract
Loading... -
+
13P - The identification of binding targets for pro-metastatic protein NIFK in lung cancer
12:30 - 12:30 | Presenter: T.C. Lin
- Abstract
Loading... -
+
14P - MMP-2 1306 C/T promoter polymorphism and smoking: A possible role as risk factors in lung cancer
12:30 - 12:30 | Presenter: A. Daniele
- Abstract
Loading... -
+
15P - Comprehensive profiling of lincRNAs in lung adenocarcinoma of never smokers reveals their important roles in cancer development and prognosis
12:30 - 12:30 | Presenter: Y. Li
- Abstract
Loading... -
+
16P - Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression
12:30 - 12:30 | Presenter: C. Qinnan
- Abstract
Loading... -
+
17P - Long non-coding RNA SNHG20 promotes non-small cell lung cancer cell progression by silencing of P21 expression
12:30 - 12:30 | Presenter: C. Zhenyao
- Abstract
Loading... -
+
18P - The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non-small cell lung cancer
12:30 - 12:30 | Presenter: W. Chenchen
- Abstract
Loading... -
+
19P - Single sample predictor of non-small cell lung cancer histology based on gene expression analysis of archival tissue
12:30 - 12:30 | Presenter: A. Karlsson
- Abstract
Loading... -
+
20P - ArgSS1 expression in squamous cell carcinoma of the lung
12:30 - 12:30 | Presenter: E. Cathcart-Rake
- Abstract
Loading... -
+
21P - Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen
12:30 - 12:30 | Presenter: M. Van Seijen
- Abstract
Loading... -
+
22P - Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma
12:30 - 12:30 | Presenter: V. Tischler
- Abstract
Loading... -
+
23P - Genomic profiling of gene aberrations in 323 Chinese NSCLC patients
12:30 - 12:30 | Presenter: Y. Liu
- Abstract
Loading... -
+
24P - Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) inhibition with AZD1208 to prevent resistance to osimertinib in EGFR mutant NSCLC
12:30 - 12:30 | Presenter: J. Bracht
- Abstract
Loading... -
+
25P - A non-pathway-specific approach in EGFR and KRAS mutant or squamous cell histology non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: M. Ito
- Abstract
Loading... -
+
26P - Incidence of T790M mutations after progression on first Line EGFR TKIS in advanced NSCLC: Real time data from a tertiary cancer institute in North India
12:30 - 12:30 | Presenter: U. Batra
- Abstract
Loading... -
+
27P - ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients
12:30 - 12:30 | Presenter: G. Metro
- Abstract
Loading... -
+
28P - The study of ALK rearrangement in advanced primary non-small cell lung cancer and associated metastatic lesions
12:30 - 12:30 | Presenter: C. Xu
- Abstract
Loading... -
+
29P - Preliminary assessment of a targeted break-point NGS assay for ALK gene fusion detection in lung adenocarcinoma samples from Chilean patients
12:30 - 12:30 | Presenter: M. Freire
- Abstract
Loading... -
+
30P - Feasibility of anti-ROS1 SP384 for detection of ROS1 protein
12:30 - 12:30 | Presenter: I. Menzl
- Abstract
Loading... -
+
31P - Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
12:30 - 12:30 | Presenter: W. Wang
- Abstract
Loading... -
+
32P - Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non-small cell lung cancer
12:30 - 12:30 | Presenter: A. Alhanafy
- Abstract
Loading... -
+
33P - Expression of biomarkers IDH1, CEA, TPA and CYFRA21-1 in peripheral blood and tissue of non-small cell lung carcinoma patients detected by real-time PCR
12:30 - 12:30 | Presenter: A. Mishra
- Abstract
Loading... -
+
34P - Recommendations for EGFR mutation testing with a fast and fully automated sample-to-result system: How to optimize DNA input instead of using lung cancer tissue?
12:30 - 12:30 | Presenter: C. Chapusot
- Abstract
Loading... -
+
Prevention, Early Detection, Epidemiology, Tobacco control
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
37P - Epidemiology and management of bronchopulmonary carcinoma in eastern Morocco of 738 cases
12:30 - 12:30 | Presenter: I. Alloubi
- Abstract
Loading... -
+
38P - Survival of lung cancer: Bangladesh perspective
12:30 - 12:30 | Presenter: R. Parveen
- Abstract
Loading... -
+
39P - Lung cancer in Morocco: Results of a retrospective study
12:30 - 12:30 | Presenter: A. Haimer
- Abstract
Loading... -
+
40P - Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status
12:30 - 12:30 | Presenter: A. Matutino
- Abstract
Loading... -
+
41P - Gender based variations in presentation and management of lung cancer at a south Asian tertiary referral centre
12:30 - 12:30 | Presenter: V. Vashistha
- Abstract
Loading... -
+
42P - Is there a delay in diagnosis of lung cancer in women?
12:30 - 12:30 | Presenter: Y. Tolwin
- Abstract
Loading... -
+
43P - A network-based signature to predict the survival of non-smoking lung adenocarcinoma
12:30 - 12:30 | Presenter: Q. Mao
- Abstract
Loading... -
+
44P - A large population-based study on large cell neuroendocrine lung cancer: A SEER database analysis
12:30 - 12:30 | Presenter: X. Fu
- Abstract
Loading... -
+
48P - Clinical characteristics of Korean lung cancer patients with programmed death-ligand 1 expression
12:30 - 12:30 | Presenter: H. Park
- Abstract
Loading... -
+
49P - Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: A systematic review and meta-analysis
12:30 - 12:30 | Presenter: J.H. Chang
- Abstract
Loading... -
+
50P - The expression and significance of miR-146a and miR-146b in BALB/c mice pulmonary precancerous lesions induced by fine particulate matter
12:30 - 12:30 | Presenter: T. Hou
- Abstract
Loading... -
+
Translational research
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
53P - Lung cancer: Beyond EGFR and ALK dichotomy
12:30 - 12:30 | Presenter: C.T. Satheesh
- Abstract
Loading... -
+
54P - Epidermal growth factor receptor expression (EGFR) in serum as a marker of treatment response and survival in advanced squamous cell lung cancer
12:30 - 12:30 | Presenter: A. Mohan
- Abstract
Loading... -
+
56P - Plasma circulating ctDNA: Potential biomarker in non-small cell lung carcinoma and clinical significance
12:30 - 12:30 | Presenter: V. Goel
- Abstract
Loading... -
+
57P - Targeted sequencing of plasma-derived cfDNA in patients with metastatic NSCLC
12:30 - 12:30 | Presenter: R. Pasquale
- Abstract
Loading... -
+
58P - Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)
12:30 - 12:30 | Presenter: C. Codony-Servat
- Abstract
Loading... -
+
59P - Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer (SCC): An exploratory sub-analysis of the LUX-Lung 8 trial
12:30 - 12:30 | Presenter: Y. Gaston Math_
- Abstract
Loading... -
+
60P - Circulating miR-31 as a predictive marker of EGFR TKI treatment efficacy in squamous cell lung cancer (SCC): A sub-analysis of the LUX-Lung 8 trial
12:30 - 12:30 | Presenter: Y. Gaston Math_
- Abstract
Loading... -
+
61P - mir-125b plays a tumor suppressor role in inflammation-related non-small cell lung cancer via repressing IGF-1 signal pathway
12:30 - 12:30 | Presenter: Y. Zhang
- Abstract
Loading... -
+
62P - MAP kinase signaling pathway in pulmonary adenocarcinomas: A study from India
12:30 - 12:30 | Presenter: V. Singh
- Abstract
Loading... -
+
63P - Prevalence and spectrum of germline mutations among patients with familial lung cancer
12:30 - 12:30 | Presenter: M. Kanwal
- Abstract
Loading... -
+
64P - Cisplatin-resistant phenotype: Characterization, adaptation to EGFR signaling and sensitivity to EGFR inhibitors in NSCLC cells
12:30 - 12:30 | Presenter: V. Pamidiboina
- Abstract
Loading... -
+
65P - Fatty acid synthase (FASN) inhibition effect on EGFR TKIs sensitive and resistant cells
12:30 - 12:30 | Presenter: S. Ruíz Martínez
- Abstract
Loading... -
+
66P - PALB2 mRNA expression as a predictive marker in advanced non-small cell lung cancer (NSCLC) patients (p) treated with docetaxel-cisplatin
12:30 - 12:30 | Presenter: N. Karachaliou
- Abstract
Loading... -
+
67P - The influence of circulating tumor DNA analysis on response to immunotherapy in non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: R. Grinberg
- Abstract
Loading... -
+
68P - In vivo study of a novel chemoablative, thermoresponsive hydrogel for intratumoural administration in a murine A549 xenograft model
12:30 - 12:30 | Presenter: S.M. Rossi
- Abstract
Loading... -
+
69P - The diabetes drug canagliflozin sensitizes non-small cell lung cancer (NSCLC) to radiotherapy and chemotherapy
12:30 - 12:30 | Presenter: T. Tsakiridis
- Abstract
Loading... -
+
70P - Immunological efficacy of anti-tumor dendritic cell vaccine application in patients with non-small cell lung cancer
12:30 - 12:30 | Presenter: O. Gorbach
- Abstract
Loading... -
+
Imaging and staging
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
73P - PET and neck US for the detection of cervical lymphadenopathy in patients with lung cancer and mediastinal lymphadenopathy
12:30 - 12:30 | Presenter: M. Ahmed
- Abstract
Loading... -
+
74P - Spatial concordance of tumor proliferation and accelerated repopulation from pathologic images to 18F-FLT PET images: A basic study guided for PET-based radiotherapy dose painting
12:30 - 12:30 | Presenter: C.M. Li
- Abstract
Loading... -
+
76P - Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
12:30 - 12:30 | Presenter: D. Vuong
- Abstract
Loading... -
+
77P - Is there an incremental benefit with 68 Ga DOTA PET/CT in staging of broncho-pulmonary carcinoid tumors?
12:30 - 12:30 | Presenter: G. Karimundackal
- Abstract
Loading... -
+
SCLC
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
79P - Small cell lung cancer in the young: Characteristics, timeliness and outcome data
12:30 - 12:30 | Presenter: S. Jiang
- Abstract
Loading... -
+
80P - Understanding the patient perspective of small cell lung cancer (SCLC)
12:30 - 12:30 | Presenter: A. Rydén
- Abstract
Loading... -
+
81P - The influence of comorbidity on health utility score (HUS) and health-related quality of life (HRQoL) in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: A. Vedadi
- Abstract
Loading... -
+
82P - Chemotherapy versus combined chemoradiotherapy: Survival patterns among patients with extensive disease small cell lung cancer
12:30 - 12:30 | Presenter: I. Uthman
- Abstract
Loading... -
+
83P - Radiotherapy improves the survival of patients with extensive disease small cell lung cancer: A propensity matched analysis of surveillance, epidemiology and end results database
12:30 - 12:30 | Presenter: R. Zhang
- Abstract
Loading... -
+
84P - Patterns of care for patients with small cell lung cancer: A survey of German radiation oncology institutions on recommendations for prophylactic cranial irradiation
12:30 - 12:30 | Presenter: C. Eze
- Abstract
Loading... -
+
85P - Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer (ES-SCLC): A tertiary cancer centre experience
12:30 - 12:30 | Presenter: A. Srivastava
- Abstract
Loading... -
+
86P - Prophylactic cranial irradiation in SCLC: A survey of German radiation oncology institutions on recommendations for brain imaging
12:30 - 12:30 | Presenter: C. Eze
- Abstract
Loading... -
+
87P - Assessment of the prognostic utility of the enumeration of circulating tumour cells at the end of treatment and disease relapse in small cell lung cancer patients
12:30 - 12:30 | Presenter: A.J. Vickers
- Abstract
Loading... -
+
88P - Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
12:30 - 12:30 | Presenter: M.J. Edelman
- Abstract
Loading... -
+
89P - The role of palliative care in extensive stage lung cancer
12:30 - 12:30 | Presenter: Y. Ahmed
- Abstract
Loading... -
+
90P - Study of intestinal flora differences between small cell lung cancer (SCLC) patients and healthy people
12:30 - 12:30 | Presenter: L. Zhang
- Abstract
Loading... -
+
Early stage NSCLC
12:30 - 12:30
- Abstract
No abstract available for this presentation
-
+
92P - Expression of TNFRII in serum is correlated with the significant risk of subcentimeter lung adenocarcinoma
12:30 - 12:30 | Presenter: Y. Zhang
- Abstract
Loading... -
+
93P - DNA damage repair protein expression and EGFR gene status in NSCLC
12:30 - 12:30 | Presenter: J. Wang
- Abstract
Loading... -
+
94P - Lung cancer recurrence in patients with pre-operative circulating tumor DNA and elevated tumor markers
12:30 - 12:30 | Presenter: S. Isaksson
- Abstract
Loading... -
+
95P - Intubated versus non-intubated general anesthesia for minimally invasive video-assisted thoracic surgery (VATS) in octogenarians
12:30 - 12:30 | Presenter: N. Ilic
- Abstract
Loading... -
+
96P - The role of bronchial stump reinforcement by flap in prevention of broncho-pleural fistula after major lung resections
12:30 - 12:30 | Presenter: F. Caushi
- Abstract
Loading... -
+
97P - Multistep prediction of cardio-pulmonary morbidity after lung cancer surgery
12:30 - 12:50 | Presenter: N. Lukavetskyy
- Abstract
Loading... -
+
98P - Trends in and impact of hospital-acquired adverse events in patients with lung cancer undergoing lung resection
12:50 - 12:50 | Presenter: A. Gupta
- Abstract
Loading... -
+
100P - Prognostic factors in surgically resected N2 small cell lung cancer: Significance of the subcarinal node
12:50 - 12:50 | Presenter: R. Qiao
- Abstract
Loading... -
+
101P - Overtreatment in early lung cancer: Survival is independent of pathological confirmation
12:50 - 12:50 | Presenter: F. Zehentmayr
- Abstract
Loading... -
+
102P - Stereotactic lung radiotherapy for early-stage NSCLC: An institution's experience
12:50 - 12:50 | Presenter: N. Ferreira
- Abstract
Loading... -
+
103P - Stereotactic body radiotherapy followed by radiofrequency ablation for inoperable stage Ib non-small cell lung cancer
12:50 - 12:50 | Presenter: H. Ding
- Abstract
Loading... -
+
104P - Adjuvant chemotherapy may improve prognosis in surgically resected stage I NSCLC with lymphovascular invasion
12:50 - 12:50 | Presenter: S. Wang
- Abstract
Loading... -
+
105P - Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected non-small cell lung cancer
12:50 - 12:50 | Presenter: R. Dokuni
- Abstract
Loading... -
+
106P - The value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma
12:50 - 12:50 | Presenter: S. Cao
- Abstract
Loading... -
+
107P - Meta-analysis on defining optimal follow up of patients with early stage NSCLC after definitive therapy
12:50 - 12:50 | Presenter: D. Wankhede
- Abstract
Loading... -
+
108TiP - A multi-center, prospective, randomized controlled clinical trial: Comparison between wedge resection and segmentectomy in the surgical treatment of ground glass opacity-dominant stage IA non-small cell lung cancer
12:50 - 12:50 | Presenter: L. Liu
- Abstract
Loading... -
+
Locally advanced NSCLC
12:50 - 12:50
- Abstract
No abstract available for this presentation
-
+
113P - Exosomal miRNAs in peripheral blood as novel diagnostic biomarkers of radioresistant lung adenocarcinoma
12:50 - 12:50 | Presenter: C. Zhu
- Abstract
Loading... -
+
114P - Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally advanced node-positive non-small cell lung cancer patients with very limited lung function
12:50 - 12:50 | Presenter: F. Manapov
- Abstract
Loading... -
+
115P - Heart and pulmonary artery radiation doses in non-small cell lung cancer
12:50 - 12:50 | Presenter: K. Thippu Jayaprakash
- Abstract
Loading... -
+
116P - Comparison of conformity and homogeneity index values of VMAT and non-VMAT techniques used in lung cancer radiotherapy
12:50 - 12:50 | Presenter: A. Ozen
- Abstract
Loading... -
+
117P - Feasibility of moderate hypofractionated image-guided thoracic irradiation for locally advanced node-positive non-small cell lung cancer patients with very limited lung function
12:50 - 12:50 | Presenter: F. Manapov
- Abstract
Loading... -
+
118P - A comparative study of sequential chemoradiation vs concurrent chemoradiation vs concurrent chemoradiation followed by consolidation chemotherapy in unresectable NSCLC
12:50 - 12:50 | Presenter: A. Datta
- Abstract
Loading... -
+
119P - Cisplatin/etoposide or paclitaxel/carboplatin with concurrent radiation therapy in stage IIIB non-small cell lung cancer: A one-year phase II trial at a low resource setting
12:50 - 12:50 | Presenter: M. Shuayb
- Abstract
Loading... -
+
120P - Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC)
12:50 - 12:50 | Presenter: N. Jokhadze
- Abstract
Loading... -
+
121P - Primary surgery followed by chemotherapy versus definitive concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
12:50 - 12:50 | Presenter: I.Z. Kiladze
- Abstract
Loading... -
+
122P - Pathological response rates after induction radio-chemotherapy in stage III NSCLC
12:50 - 12:50 | Presenter: F. Casas
- Abstract
Loading... -
+
124P - Cardiac events in stage III non-small cell lung cancer (NSCLC): An attention shift to cardio-oncology collaboration
12:50 - 12:50 | Presenter: J. Degens
- Abstract
Loading... -
+
125P - Brain metastases in patients with stage N2 non-small cell lung cancer
12:50 - 12:50 | Presenter: C. Lowrie
- Abstract
Loading... -
+
126TiP - SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC): A multicenter single-arm phase II trial
12:50 - 12:50 | Presenter: S.I. Rothschild
- Abstract
Loading... -
+
127TiP - Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574)
12:50 - 12:50 | Presenter: T. Tsakiridis
- Abstract
Loading... -
+
Advanced NSCLC
12:50 - 12:50
- Abstract
No abstract available for this presentation
-
+
145P - Impact of next-generation sequencing on survival in lung cancer
12:50 - 12:50 | Presenter: S. Geva
- Abstract
Loading... -
+
146P - The clinical impact of comprehensive cfDNA genomic testing in lung cancer
12:50 - 12:50 | Presenter: S. Geva
- Abstract
Loading... -
+
147P - Clinical testing of ctDNA from NSCLC patients using A 17-gene liquid biopsy mutation panel
12:50 - 12:50 | Presenter: D.A. Eberhard
- Abstract
Loading... -
+
148P - Method comparison for detection of epidermal growth factor receptor (EGFR) T790M mutation in matched biopsied tumour sections and plasma samples
12:50 - 12:50 | Presenter: J. Longshore
- Abstract
Loading... -
+
149P - Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction
12:50 - 12:50 | Presenter: N. Tokaca
- Abstract
Loading... -
+
150P - Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study
12:50 - 12:50 | Presenter: M. Gottfried
- Abstract
Loading... -
+
151P - Maintenance therapy using tyrosine kinase inhibitor (erlotinib) or pemetrexed in metastatic/locally advanced in EGFR mutation-negative lung cancer: Comparison of results
12:50 - 12:50 | Presenter: K. Gupta
- Abstract
Loading... -
+
152P - Impaired liver function was associated with PFS of EGFR TKI treatment
12:50 - 12:50 | Presenter: Q. Zhu
- Abstract
Loading... -
+
153P - EGFR T790M co-exists with sensitive mutations in the same cell group in lung adenocarcinoma patients
12:50 - 12:50 | Presenter: X. Shi
- Abstract
Loading... -
+
154P - CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: Real world data
12:50 - 12:50 | Presenter: R. Devjak
- Abstract
Loading... -
+
155P - Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models
12:50 - 12:50 | Presenter: F. Morgillo
- Abstract
Loading... -
+
156P - ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
12:50 - 12:50 | Presenter: D. Vicente Baz
- Abstract
Loading... -
+
157P - Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study
12:50 - 12:50 | Presenter: S. Thongprasert
- Abstract
Loading... -
+
158P - Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: Overview of clinical data
12:50 - 12:50 | Presenter: A. Märten
- Abstract
Loading... -
+
159P - Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study
12:50 - 12:50 | Presenter: M.T. Moran Bueno
- Abstract
Loading... -
+
160P - Real world study of lung squamous cell carcinoma patients with EGFR mutation treated with EGFR-TKI
12:50 - 12:50 | Presenter: L. Miao
- Abstract
Loading... -
+
161P - The survival of advanced non-small cell lung cancer with epidermal growth factor receptor in Thailand: A single instituition review
12:50 - 12:50 | Presenter: A. Supavavej
- Abstract
Loading... -
+
162P - Responses to EGFR TKIs and ALK TKIs in advanced NSCLC patients harboring concomitant EGFR and ALK alterations
12:50 - 12:50 | Presenter: S. Wang
- Abstract
Loading... -
+
163P - The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network
12:50 - 12:50 | Presenter: J. Roeper
- Abstract
Loading... -
+
164P - Feasibility of liquid biopsy using plasma and platelets for detection of ALK rearrangements in non-small cell lung cancer
12:50 - 12:50 | Presenter: C. Park
- Abstract
Loading... -
+
165P - Analysis of our experience of ROS-1 patients in advanced NSCLC
12:50 - 12:50 | Presenter: N. Pande
- Abstract
Loading... -
+
166P - Evidence-based conclusions and inclinations of pemetrexed, taxane and bevacizumab in advanced lung cancer
12:50 - 12:50 | Presenter: S. Shaheen
- Abstract
Loading... -
+
167P - Efficacy of pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with ROS-1 rearrangement
12:50 - 12:50 | Presenter: B. Zhang
- Abstract
Loading... -
+
168P - Pemetrexed dosing regimens in patients with advanced NSCLC
12:50 - 12:50 | Presenter: S. Visser
- Abstract
Loading... -
+
169P - Nephrotoxicity of pemetrexed maintenance in patients with advanced NSCLC: Two cohort studies
12:50 - 12:50 | Presenter: S. Visser
- Abstract
Loading... -
+
170P - A phase II trial of nab-paclitaxel and gemcitabine in patients with non-small cell lung cancer previously treated with platinum based chemotherapy
12:50 - 12:50 | Presenter: Y. Hatakeyama
- Abstract
Loading... -
+
171P - A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer
12:50 - 12:50 | Presenter: Y. Kono
- Abstract
Loading... -
+
172P - Safety and efficacy phase 2 study of nab-paclitaxel maintenance treatment after nab-paclitaxel plus carboplatin in stage IIIB/IV non-small cell lung cancer
12:50 - 12:50 | Presenter: A. Nakao
- Abstract
Loading... -
+
173P - Apatinib plus S-1 showes encouraging response in advanced non-small-cell lung canceras as laterline chemotherapy
12:50 - 12:50 | Presenter: Z. wu
- Abstract
Loading... -
+
174P - Aprepitant, palonosetron and dexamethasone proved effective to prevent chemotherapy-related nausea and vomiting in lung cancer
12:50 - 12:50 | Presenter: Y. Zhang
- Abstract
Loading... -
+
175P - A prospective, randomized, double-blind study of pre-chemotherapy hydration with or without mannitol to prevent renal toxicity in non-small cell lung cancer (NSCLC) patients receiving cisplatin-gemcitabine chemotherapy
12:50 - 12:50 | Presenter: N. Thavornpattanpong
- Abstract
Loading... -
+
176P - PrediCare: A new diagnostic tool predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of three serum biomarkers
12:50 - 12:50 | Presenter: Y. Kogan
- Abstract
Loading... -
+
177P - Clinicopathologic characteristics in large cell neuroendocrine carcinomas of the lung (LCNCL): The experience of one center
12:50 - 12:50 | Presenter: M. Vaslamatzis
- Abstract
Loading... -
+
178P - Smo inhibitor LDE225 reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells
12:50 - 12:50 | Presenter: Y. Yu
- Abstract
Loading... -
+
179P - The cytoplasmic LKB1 promotes the growth of human lung adenocarcinoma by enhancing autophagy
12:50 - 12:50 | Presenter: M.J. Liu
- Abstract
Loading... -
+
180P - Significant progress in palliative treatment of NSCLC over the last decades: Correlation of treatment milestones with survival in unselected patients
12:50 - 12:50 | Presenter: S.I. Rothschild
- Abstract
Loading... -
+
181P - Real-world comparative effectiveness of treatment sequences in metastatic non-small cell lung cancer with squamous histology
12:50 - 12:50 | Presenter: H. Yang
- Abstract
Loading... -
+
182P - Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non-small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis
12:50 - 12:50 | Presenter: R. Tassi
- Abstract
Loading... -
+
183P - Progression of central nervous system metastases in advanced non-small cell lung cancer patients effectively treated with first-generation EGFR-TKI
12:50 - 12:50 | Presenter: M. Yu
- Abstract
Loading... -
+
184P - Clinico-radiological pattern of response to nivolumab in stage IV NSCL: A real life experience over two years
12:50 - 12:50 | Presenter: M. Perna
- Abstract
Loading... -
+
185P - Retrospective study of tumour responses and toxicities associated with anti-PD1 antibody therapy in elderly cancer patients(>75yo) in comparison to patients ≤75yo with metastatic non-small cell lung cancer
12:50 - 12:50 | Presenter: L.C. CHONG
- Abstract
Loading... -
+
186P - Thyroid toxicity as an immune-related adverse event in patients with non-small cell lung cancer during treatment with immune checkpoint inhibitors
12:50 - 12:50 | Presenter: K. Syrigos
- Abstract
Loading... -
+
187P - Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response
12:50 - 12:50 | Presenter: J. Rogado
- Abstract
Loading... -
+
188P - Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
12:50 - 12:50 | Presenter: M. Reck
- Abstract
Loading... -
+
189P - Are pretreatment neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and advanced lung cancer inflamation index (ALI) levels useful in predicting the outcomes of patients with advanced non-small cell lung cancer?
12:50 - 12:50 | Presenter: B. Komurcuoglu
- Abstract
Loading... -
+
190P - Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of nivolumab outcome and toxicity in NSCLC?
12:50 - 12:50 | Presenter: J. Rogado
- Abstract
Loading... -
+
192P - KRAS as predictive biomarker of response to checkpoint inhibitors in NSCLC
12:50 - 12:50 | Presenter: A. Addeo
- Abstract
Loading... -
+
193TiP - Phase 3 study of epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715
12:50 - 12:50 | Presenter: M. Garassino
- Abstract
Loading... -
+
194TiP - eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
12:50 - 12:50 | Presenter: L. Horn
- Abstract
Loading... -
+
195TiP - A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)
12:50 - 12:50 | Presenter: L. Paz-Ares
- Abstract
Loading... -
+
196TiP - CheckMate 384: A phase 3b/4 dose-frequency optimization trial of nivolumab in advanced or metastatic NSCLC
12:50 - 12:50 | Presenter: E. Garon
- Abstract
Loading... -
+
197TiP - A phase 1/2 trial of selinexor combined with docetaxel for previously treated, advanced KRAS mutant non-small cell lung cancer
12:50 - 12:50 | Presenter: A. Gupta
- Abstract
Loading... -
+
198TiP - Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study
12:50 - 12:50 | Presenter: N. Karachaliou
- Abstract
Loading... -
+
199TiP - TTFields concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study
12:50 - 12:50 | Presenter: U. Weinberg
- Abstract
Loading... -
+
Metastases to and from the lung
12:50 - 12:50
- Abstract
No abstract available for this presentation
-
+
201P - Isolation of circulating tumor cells and potential heterogeneity analysis in advanced non-small cell lung cancer
12:50 - 12:50 | Presenter: H. Zhang
- Abstract
Loading... -
+
202P - The clone evolutionary landscape and genomic characteristics of osteosarcoma and lung metastasis
12:50 - 12:50 | Presenter: J. Lai
- Abstract
Loading... -
+
203P - Combined pulmonary metastasectomy and chemotherapy in patients with colorectal lung metastases and concurrent extrapulmonary disease
12:50 - 12:50 | Presenter: M. Faisal
- Abstract
Loading... -
+
204P - Clinicopathological features, treatment patterns and outcomes of pulmonary metastasectomy
12:50 - 12:50 | Presenter: P. Shivanna
- Abstract
Loading... -
+
205P - RNA-seq analysis of lung adenocarcinomas reveals different circular RNA expression profiles between non-metastatic and metastatic patients
12:50 - 12:50 | Presenter: D. Wu
- Abstract
Loading... -
+
206P - Isolated splenic metastasis from non-small cell lung cancer: Study of an extremely rare clinical entity with review of all cases reported in the literature
12:50 - 12:50 | Presenter: N. Mitsimponas
- Abstract
Loading... -
+
207P - A comparison of outcomes of stereotactic body radiotherapy versus metastasectomy in patients with pulmonary metastases
12:50 - 12:50 | Presenter: Y.H. Lee
- Abstract
Loading... -
+
208P - Metastatic non-small cell lung carcinoma: About 420 cases
12:50 - 12:50 | Presenter: H. Loubna
- Abstract
Loading... -
+
209P - The management of brain disease (BD) in ALK-rearranged non-small cell lung cancer (ALK NSCLC): Can systemic treatment delay the initiation of local treatments? Experience of the Ramón y Cajal University Hospital (RyCUH, Madrid)
12:50 - 12:50 | Presenter: R. Martin Huertas
- Abstract
Loading... -
+
210P - Brain oligometastases in NSCLC: Therapeutic effect and prognostic factors of WBRT combined with intracarotid infusion of elemene
12:50 - 12:50 | Presenter: Y. XU
- Abstract
Loading... -
+
211P - First analysis of a real-world study to explore the character and treatment outcome of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) on non-small cell lung cancer (NSCLC) with brain metastases (BM)
12:50 - 12:50 | Presenter: H. Zhang
- Abstract
Loading... -
+
212P - Clinical experience and predictive factors of response to whole brain radiotherapy in metastatic lung cancer: A single institute experience
12:50 - 12:50 | Presenter: V.V. Pareek
- Abstract
Loading... -
+
Mesothelioma
12:50 - 12:50
- Abstract
No abstract available for this presentation
-
+
217P - Impact of VEGF and CD74 expression on response and survival of malignant pleural mesothelioma patients treated with gemcitabine and cisplatin: A phase II retrospective study
12:50 - 12:50 | Presenter: D.A. Soliman
- Abstract
Loading... -
+
219P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)
12:50 - 12:50 | Presenter: S. Cedres Perez
- Abstract
Loading... -
+
220P - Effects of pifithrin-μ on the growth of acidity-tolerant malignant mesothelioma cells and epithelial-mesenchymal transition
12:50 - 12:50 | Presenter: S. Lee
- Abstract
Loading... -
+
221P - Treatment experience of pleural malignant mesothelioma in a tertiary referral center in Mexico
12:50 - 12:50 | Presenter: A.M. Gutierrez
- Abstract
Loading... -
+
222P - Women: The other face of malignant pleural mesothelioma
12:50 - 12:50 | Presenter: M.E. Brandão
- Abstract
Loading... -
+
Miscellaneous
12:50 - 12:50
- Abstract
No abstract available for this presentation
-
+
223P - Sarcomatoid lung carcinoma: An uncommon and deadly entity
12:50 - 12:50 | Presenter: A. Sharma
- Abstract
Loading... -
+
224P - The role of surgery in the treatment of lung neuroendocrine tumors (NETs) based on a 3-year experience of a thoracic department
12:50 - 12:50 | Presenter: B. von Amann
- Abstract
Loading... -
+
225P - Surgical experience of advanced bronchopulmonary carcinoids: An analysis from a tertiary care hospital of North India
12:50 - 12:50 | Presenter: N. Kumar
- Abstract
Loading... -
+
226P - Accuracy of mutation analysis in small tissues from transbronchial lung biopsy with radial probe endobronchial ultrasound
12:50 - 12:50 | Presenter: M.K. Lee
- Abstract
Loading... -
+
227P - Stereotactic body radiotherapy with helical tomotherapy for lung tumors: A single-center experience
12:50 - 12:50 | Presenter: V. Figlia
- Abstract
Loading... -
+
228P - Augmentation of NAD+ by NQO1 activation attenuates cisplatin-mediated hearing impairment
12:50 - 12:50 | Presenter: S. Yang
- Abstract
Loading... -
+
229P - Clinical and laboratory markers of prognosis in lung cancer patients with hypercalcemia
12:50 - 12:50 | Presenter: K. Syrigos
- Abstract
Loading... -
+
230P - Experience with the implant of vascular access devices by medical oncologists in a non-surgical setting
12:50 - 12:50 | Presenter: A. Revuelta
- Abstract
Loading... -
+
231P_PR - Impact of the continuity of nursing care delivered by a pivot nurse in oncology on improving satisfaction and quality of life of patients with advanced lung cancer
12:50 - 12:50 | Presenter: E. Kassouf
- Abstract
Loading... -
+
232TiP - Lanreotide autogel/depot in lung neuroendocrine tumours: The randomized, double-blind, placebo-controlled, international phase 3 SPINET Study
12:50 - 12:50 | Presenter: X.M. Truong Thanh
- Abstract
Loading...
-
+
Industry Satellite Symposium 6
- Type: Industry Satellite Symposium
- Presentations: 0
- Coordinates: 4/13/2018, 13:00 - 14:00, Room A
-
+
Industry Satellite Symposium 7
- Type: Industry Satellite Symposium
- Presentations: 0
- Coordinates: 4/13/2018, 13:00 - 14:00, Room C
-
+
Keynote lecture
- Type: Keynote Lecture
- Presentations: 1
- Moderators:M. Reck
- Coordinates: 4/13/2018, 14:10 - 14:40, Room B
-
+
Predictive biomarkers for immune checkpoints inhibitors
14:10 - 14:40 | Presenter: O. Michielin
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Epidemiology and outcomes
- Type: Poster Discussion session
- Presentations: 11
- Moderators:A. Dingemans
- Coordinates: 4/13/2018, 14:45 - 15:45, Room W
-
+
35PD - Magnitude of exposure to biomass fuel smoke and risk of lung cancer in women: Cases and controls study
10:59 - 10:59 | Presenter: R. Baez-Saldana
- Abstract
Loading... -
+
36PD - New demographic characteristics of lung cancer patients in East Asia? Practice of low-dose spiral computed tomography screening in Shanghai major hospitals
10:59 - 10:59 | Presenter: X. Luo
- Abstract
Loading... -
+
71PD - Emergency department incidental lung nodule follow up: A best practice initiative
10:59 - 10:59 | Presenter: K..A. Lee
- Abstract
Loading... -
+
72PD - MR imaging radiomics of NSCLC brain metastases: A potential targetable imaging biomarker for EGFR status
10:59 - 10:59 | Presenter: A. Mahajan
- Abstract
Loading... -
+
200PD - High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center
10:59 - 10:59 | Presenter: C. Fahim
- Abstract
Loading... -
+
Invited Discussant 35PD, 36PD, 71PD, 72PD and 200PD
14:45 - 15:05 | Presenter: A. Dingemans
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
15:05 - 15:20
- Abstract
No abstract available for this presentation
-
+
215PD - Survival patterns in patients with malignant pleural mesothelioma using multimodality therapy
10:59 - 10:59 | Presenter: M. Hassan
- Abstract
Loading... -
+
216PD - Should radical surgery be performed in non-epithelioid malignant pleural mesothelioma?
10:59 - 10:59 | Presenter: L. Lang-Lazdunski
- Abstract
Loading... -
+
Invited Discussant 215PD and 216PD
15:20 - 15:35 | Presenter: D. Fennell
- Abstract
No abstract available for this presentation
-
+
Discussion
15:35 - 15:45
- Abstract
No abstract available for this presentation
-
+
Guiding the best targeted treatment
- Type: Multidisciplinary Tumour Board
- Presentations: 3
- Moderators:E. Smit
- Coordinates: 4/13/2018, 14:45 - 16:15, Room A
-
+
Can we rely on liquid biopsy for treatment decision at the time of acquired resistance?
14:45 - 15:15 | Presenter: J. Remon-Masip
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
EGFR activating mutation plus exon 20 co-mutation at baseline: Which TKI should we select for frontline treatment?
15:15 - 15:45 | Presenter: E. Smit
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Progression on osimertinib: When is it possible to continue with a targeted therapy?
15:45 - 16:15 | Presenter: D. Planchard
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Less frequent driving alterations
- Type: Educational session
- Presentations: 5
- Moderators:E. Felip
- Coordinates: 4/13/2018, 14:45 - 16:15, Room C
-
+
MET
14:45 - 15:05 | Presenter: A. Cortot
- Abstract
No abstract available for this presentation
-
+
BRAF
15:05 - 15:25 | Presenter: C. Rolfo
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
RET and NTRK
15:25 - 15:45 | Presenter: R. Doebele
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
HER2 and others
15:45 - 16:05 | Presenter: E. Felip
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
16:05 - 16:15
- Abstract
No abstract available for this presentation
-
+
Coffee break
- Type: Coffee break
- Presentations: 0
- Coordinates: 4/13/2018, 16:15 - 16:45, Hall 1
-
+
5th ESO Lung Cancer Observatory
- Type: Special session
- Presentations: 9
- Moderators:M.S. Aapro
- Coordinates: 4/13/2018, 16:45 - 18:15, Room W
-
+
Tobacco control, strategies and figures: What’s next?
16:45 - 16:55 | Presenter: C. Adams
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Lung cancer screening in 2019?
16:55 - 17:05 | Presenter: H. De Koning
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Early-stage NSCLC, next steps: Staging, surgery, molecular determinations
17:05 - 17:15 | Presenter: P. Van Schil
- Abstract
No abstract available for this presentation
-
+
Radiation oncology: New approaches in 2019
17:15 - 17:25 | Presenter: F. Mornex
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
What to ask your pathologist today and in 2019?
17:25 - 17:35 | Presenter: K. Kerr
- Abstract
No abstract available for this presentation
-
+
Developments in immunotherapy: What practice changing studies will mature in 2019?
17:35 - 17:45 | Presenter: B. Besse
- Abstract
No abstract available for this presentation
-
+
Developments in targeted therapies: What practice changing studies will mature in 2019?
17:45 - 17:55 | Presenter: E. Felip
- Abstract
No abstract available for this presentation
-
+
The patient’s perspective
17:55 - 18:05 | Presenter: F. Johansson
- Abstract
No abstract available for this presentation
-
+
Panel discussion
18:05 - 18:15
- Abstract
No abstract available for this presentation
first
prev
